银屑病患者在接受白细胞介素23抑制剂治疗时的超级应答者：两个中心的经验 - Suppr | 超能文献

Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres.

作者信息

Menéndez Sánchez M, Muñiz de Lucas A, Pérez Fernández E, Llamas Velasco M, Ruiz Genao D P, López Estébaranz J L

机构信息

Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

Department of Preventive Medicine, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

出版信息

J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1321-e1322. doi: 10.1111/jdv.19310. Epub 2023 Jul 13.

DOI:10.1111/jdv.19310

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres.银屑病患者在接受白细胞介素23抑制剂治疗时的超级应答者：两个中心的经验

J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1321-e1322. doi: 10.1111/jdv.19310. Epub 2023 Jul 13.

2

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).在依那西普无反应者中转换为司库奇尤单抗的疗效和安全性：来自两项中重度斑块状银屑病III期随机临床试验（UNCOVER-2和-3）的亚组分析

Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.

3

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.在银屑病患者中，依那西普可降低血清白细胞介素-17和白细胞介素-22水平，但阿维A则无此作用：一项随机对照试验。

J Clin Immunol. 2009 Mar;29(2):210-4. doi: 10.1007/s10875-008-9233-0. Epub 2008 Sep 2.

4

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.乌司奴单抗与依那西普治疗中重度银屑病的比较。

N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652.

5

Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry.在Corrona银屑病登记处登记的中度至重度银屑病患者中，对白细胞介素-17抑制剂无反应者的特征分析。

J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e531-e533. doi: 10.1111/jdv.17270. Epub 2021 Apr 27.

6

Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.血清白细胞介素-17A 与托法替尼和依那西普治疗中重度银屑病的临床应答的相关性。

Clin Exp Dermatol. 2018 Oct;43(7):790-797. doi: 10.1111/ced.13561. Epub 2018 May 10.

7

Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.在德国，与其他生物制剂相比，司库奇尤单抗作为中度至重度银屑病的一线生物治疗的成本效益。

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-2199. doi: 10.1111/jdv.15047. Epub 2018 Jun 27.

8

Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.在意大利临床实践中用依那西普治疗银屑病：停药后的处方实践和缓解持续时间。

Clin Drug Investig. 2010;30(8):507-16. doi: 10.2165/11537470-000000000-00000.

9

Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.TNF 抑制剂和 IL12/23 抑制剂对银屑病患者体重和脂肪因子水平变化的影响：一项为期 48 周的比较研究。

J Dermatolog Treat. 2022 May;33(3):1727-1732. doi: 10.1080/09546634.2021.1901845. Epub 2022 Mar 23.

10

Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.依那西普浓度与银屑病面积和严重程度指数量表值的降低之间呈正相关。

Int J Clin Pharm. 2016 Oct;38(5):1142-8. doi: 10.1007/s11096-016-0343-0. Epub 2016 Jul 19.

引用本文的文献

1

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.鉴定在真实临床实践中接受度伐鲁单抗治疗的银屑病患者中对其有最佳应答的遗传多态性。

Exp Dermatol. 2024 Aug;33(8):e15152. doi: 10.1111/exd.15152.